By John S. MacNeil
“Am I suggesting that all NIH researchers become drug developers?” asked Francis Collins at the annual BIO meeting this summer. Although he answered himself with an emphatic “No!”, that he asked the question at all is noteworthy. In a paper published in Nature last April, Collins first raised the idea of the National Human Genome Research Institute participating more actively in early-stage drug discovery. At BIO he made the institute’s plans more explicit.